Free tool
FAERS Monitor: Betimol
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020439 or its brand name (Betimol, Timolol). Reports on generic versions are filed under their own applications.
Reports
12,185
Serious
5,726
47% of reports
Hospitalization
2,394
Death reported
584
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure3,052
- drug ineffective817
- fatigue493
- hypersensitivity461
- off label use418
- dizziness415
- diarrhoea409
- dyspnoea368
- nausea366
- eye irritation362
- fall332
- headache317
- eye pain312
- vision blurred297
- intraocular pressure increased286
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 15 |
| 2006 | 17 |
| 2007 | 9 |
| 2008 | 61 |
| 2009 | 94 |
| 2010 | 116 |
| 2011 | 164 |
| 2012 | 164 |
| 2013 | 325 |
| 2014 | 433 |
| 2015 | 568 |
| 2016 | 670 |
| 2017 | 674 |
| 2018 | 850 |
| 2019 | 903 |
| 2020 | 3,868 |
| 2021 | 615 |
| 2022 | 546 |
| 2023 | 551 |
| 2024 | 470 |
| 2025 | 591 |
| 2026 | 474 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,974 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 3,052 | 66.0 | 63.9 | 188,814 |
| intraocular pressure increasedSignal | 286 | 39.5 | 35.2 | 10,458 |
| eye irritationSignal | 362 | 10.9 | 9.9 | 3,240 |
| eye painSignal | 312 | 9.6 | 8.6 | 2,386 |
| hypersensitivitySignal | 461 | 4.3 | 3.9 | 1,169 |
| vision blurredSignal | 297 | 3.7 | 3.3 | 596 |
| fall | 332 | 1.7 | 1.5 | 101 |
| dizziness | 415 | 1.4 | 1.3 | 56 |
| dyspnoea | 368 | 1.1 | 1.0 | 5 |
| diarrhoea | 409 | 1.1 | 1.0 | 3 |
| fatigue | 493 | 1.1 | 1.0 | 4 |
| drug ineffective | 817 | 1.1 | 1.0 | 4 |
| headache | 317 | 0.9 | 0.8 | 6 |
| off label use | 418 | 0.8 | 0.7 | 16 |
| nausea | 366 | 0.8 | 0.7 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.